Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy

Autor: Bychkov, D. (Dmitrii), Linder, N. (Nina), Tiulpin, A. (Aleksei), Kücükel, H. (Hakan), Lundin, M. (Mikael), Nordling, S. (Stig), Sihto, H. (Harri), Isola, J. (Jorma), Lehtimäki, T. (Tiina), Kellokumpu-Lehtinen, P.-L. (Pirkko-Liisa), von Smitten, K. (Karl), Joensuu, H. (Heikki), Lundin, J. (Johan)

Publikováno v: Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)

The treatment of patients with ERBB2 (HER2)-positive breast cancer with anti-ERBB2 therapy is based on the detection of ERBB2 gene amplification or protein overexpression. Machine learning (ML) algorithms can predict the amplification of ERBB2 based

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f62cbfe26cee97bcf4f5263f58e2dccb
http://hdl.handle.net/10138/327960

One-year morbidity after sentinel node biopsy and breast surgery

Autor: Rönkä, R. ^*, von Smitten, K., Tasmuth, T., Leidenius, M.

Publikováno v: In The Breast 2005 14(1):28-36

Outcome and Biomarker Supervised Deep Learning for Survival Prediction in Two Multicenter Breast Cancer Series.

Autor: Bychkov D; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Program, Helsinki, Finland., Joensuu H; iCAN Digital Precision Cancer Medicine Program, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland., Nordling S; Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland., Tiulpin A; Research Unit of Medical Imaging, Physics and Technology, University of Oulu, Oulu, Finland.; Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland.; Ailean Technologies Oy, Oulu, Finland., Kücükel H; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Program, Helsinki, Finland., Lundin M; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland., Sihto H; Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland., Isola J; Department of Cancer Biology, BioMediTech, University of Tampere, Tampere, Finland., Lehtimäki T; Helsinki University Hospital, Helsinki, Finland., Kellokumpu-Lehtinen PL; Department of Oncology, Tampere University Hospital, Tampere, Finland., von Smitten K; Eira Hospital, Helsinki, Finland., Lundin J; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Program, Helsinki, Finland.; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden., Linder N; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Program, Helsinki, Finland.; Department of Women's and Children's Health, International Maternal and Child Health, Uppsala University, Uppsala, Sweden.

Publikováno v: Journal of pathology informatics [J Pathol Inform] 2022 Jan 18; Vol. 13, pp. 9. Date of Electronic Publication: 2022 Jan 18 (Print Publication: 2022).

Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy.

Autor: Bychkov D; Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland. dmitrii.bychkov@helsinki.fi.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. dmitrii.bychkov@helsinki.fi., Linder N; Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Department of Women's and Children's Health, International Maternal and Child Health, Uppsala University, Uppsala, Sweden., Tiulpin A; Physics and Technology, Research Unit of Medical Imaging, University of Oulu, Oulu, Finland.; Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland.; Ailean Technologies Oy, Oulu, Finland., Kücükel H; Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Lundin M; Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland., Nordling S; Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland., Sihto H; Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland., Isola J; Department of Cancer Biology, BioMediTech, University of Tampere, Tampere, Finland., Lehtimäki T; Helsinki University Hospital, Helsinki, Finland., Kellokumpu-Lehtinen PL; Department of Oncology, Tampere University Hospital, Tampere, Finland., von Smitten K; Eira Hospital, Helsinki, Finland., Joensuu H; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Lundin J; Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Publikováno v: Scientific reports [Sci Rep] 2021 Feb 17; Vol. 11 (1), pp. 4037. Date of Electronic Publication: 2021 Feb 17.

Two Different Immune Profiles Are Identified in Sentinel Lymph Nodes of Early-Stage Breast Cancer.

Autor: Ribeiro, Joana Martins¹ (AUTHOR) joana.ribeiro@fmed.uc.pt, Mendes, João^1,2 (AUTHOR), Gante, Inês^3,4 (AUTHOR), Figueiredo-Dias, Margarida^3,4 (AUTHOR), Almeida, Vânia^5,6 (AUTHOR), Gomes, Ana⁵ (AUTHOR), Regateiro, Fernando Jesus¹ (AUTHOR), Regateiro, Frederico Soares^2,7,8 (AUTHOR), Caramelo, Francisco^2,9,10 (AUTHOR), Silva, Henriqueta Coimbra^1,2,10 (AUTHOR)

Publikováno v: Cancers. Aug2024, Vol. 16 Issue 16, p2881. 17p.